Impact of PD-1 inhibitor immunotherapy on survival in patients with newly diagnosed and recurrent glioblastoma: a systematic review of comparative evidence
Folia Medica · 13.08.2026 · 68 (4)
DOI: 10.3897/folmed.68.e184377 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Folia Medica, online erschienen am 13.08.2026. Verfasst von Renindra Ananda Aman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia-Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Immunotherapy, Neoplasm Recurrence, Local. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Introduction
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. PD-1 inhibitors have shown potential use in GBM. There is some evidence to suggest that programmed death-1 (PD-1) inhibitors may be effective in treating GBM. However, the results of clinical trials conducted to date have been inconclusive, which has led to questions regarding the efficacy of PD-1 inhibitors in this context.
Aim
This systematic review aimed to evaluate whether PD-1 inhibitors provide a survival advantage over the standard regimens in GBM. Materials and methods : This review followed the PRISMA guidelines. Comprehensive searches were conducted in PubMed, Scopus, and the Cochrane Library from 2015 to 2025. The extracted data included the study design, sample characteristics, interventions, comparators, and reported survival outcomes. The risk of bias was assessed using the Cochrane RoB 2 tool.
Results
Four trials were included in this review. In newly diagnosed GBM, PD-1 inhibitors plus radiotherapy showed an inferior overall survival (OS) rate compared to standard regimens (median OS [mOS] 13.4 vs. 14.9 months, HR 1.31 [95% CI: 1.09-1.58]). PD-1 inhibitors as an adjuvant to temozolomide-based therapy also showed no statistically significant improvement in OS (mOS 11.6 vs. 11.8 months, HR 0.85 [95% CI 0.54-1.33]) or progression-free survival (PFS) (median PFS [mPFS] 7.4 vs. 5.9 months, HR 0.77 [95% CI 0.49- 1.19]) compared to placebo. For recurrent GBM, there was no significant difference in OS between nivolumab and bevacizumab (mOS 11.6 vs. 10.0 months, HR 1.04 [95% CI: 0.83-1.3]). Consistently, PD-1 inhibitors did not demonstrate a survival advantage in either newly diagnosed or recurrent glioblastoma.
Conclusion
PD-1 inhibitors showed no statistically significant improvement in OS and PFS in patients with GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia-Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
ORCID-Profile: Renindra Ananda Aman
Zitieren
APA
Aman, R. A., Wayne, T. M. L. S., Hamdilah, F., & Adriantama, M. W. (2026). Impact of PD-1 inhibitor immunotherapy on survival in patients with newly diagnosed and recurrent glioblastoma: a systematic review of comparative evidence. Folia Medica, 68(4). https://doi.org/10.3897/folmed.68.e184377
Vancouver
Aman RA, Wayne TMLS, Hamdilah F, Adriantama MW. Impact of PD-1 inhibitor immunotherapy on survival in patients with newly diagnosed and recurrent glioblastoma: a systematic review of comparative evidence. Folia Medica. 2026;68(4). doi:10.3897/folmed.68.e184377
BibTeX
@article{Aman2026,
author = {Aman, Renindra Ananda and Wayne, Theresia Meiske Laura Siscawati and Hamdilah, Fadli and Adriantama, Muhammad Wasistha},
title = {Impact of PD-1 inhibitor immunotherapy on survival in patients with newly diagnosed and recurrent glioblastoma: a systematic review of comparative evidence},
journal = {Folia Medica},
year = {2026},
volume = {68},
number = {4},
doi = {10.3897/folmed.68.e184377}
}
EUVIMED